NIH halted trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
On Mar. 2, 2021, the National Institutes of Health (NIH) halted a clinical trial evaluating the safety and…
-
-
Innovation Pharma announced publication in Journal Viruses on the anti-SARS-CoV-2 properties of brilacidin
On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyﾒs international Phase 2…
-
Innovation Pharma provided study details for phase 2 clinical trial of Brilacidin in hospitalized COVID-19 patients
On Feb. 26, 2021, Innovation Pharmaceuticals announced that after an interim review, by an independent Data Monitoring Committee…
-
Novavax and Takeda finalized license agreement for Novavax COVID-19 vaccine candidate in Japan
On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takeda’s development, manufacturing and…
-
Altimmune commenced enrollment in phase 1 trial of AdCOVID needle-free, single-dose Intranasal COVID-19 vaccine candidate
On Feb. 25, 2021, Altimmune announced that it had commenced enrollment in a Phase 1 clinical trial of…
-
NeuroRx announced that ZYESAMI (Aviptadil) had successfully demonstrated accelerated recovery from Covid-19 respiratory failure
On Feb. 24, 2021, NeuroRx, announced that the phase 2b/3 trial of ZYESAMI for the treatment of Respiratory…
-
Monoclonal antibodies against MERS Coronavirus showed promise in phase 1 NIH-sponsored trial
On Feb. 23, 2021, the NIH announced that a randomized, placebo-controlled Phase 1 clinical trial of two monoclonal…
-
Novavax completed enrollment of PREVENT-19, COVID-19 vaccine pivotal phase 3 trial in the US and Mexico
On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in…
-
Johnson & Johnson announces submission to WHO for EUL of investigational single-shot COVID-19 vaccine candidate
On Feb. 19, 2021, Johnson & Johnson announced that Janssen-Cilag had submitted for Emergency Use Listing (EUL) to…
-
World’s largest clinical trial for COVID-19 treatments expanded internationally
On Feb. 18, 2021, scientists at the University of Oxford announced that the Randomised Evaluation of COVID-19 Therapy…
-
Novavax announced MOU with Gavi for cumulative supply to COVAX facility of 11 billion doses of COVID-19 vaccine
On Feb. 18, 2021, Novavax and announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to…
-
Plans underway for pediatric COVID-19 vaccine trials
On Feb. 18, 2021, Washington University pediatric infectious diseases doctors announced plans to launch clinical trials in the…
-
Altimmune announced FDA clearance of AdCOVID IND application
On Feb. 17, 2021, Altimmune announced that the U.S. Food and Drug Administration (FDA) had cleared the Companyls…
-
Anixa Biosciences began animal Testing of Covid-19 therapeutic candidates
On Feb. 16, 2021, Anixa Biosciences announced that animal testing had commenced with two proprietary compounds that have…
-
Johnson & Johnson announced submission of Marketing Authorisation Application to EMA for Janssen COVID-19 vaccine candidate
On Feb. 16, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, has submitted a conditional Marketing Authorisation…
-
Novavax announced expanded agreement with SK Bioscience for 40 million doses of COVID-19 vaccine for South Korea
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
-
DOD participated in COVID-19 antibody treatment trial
On Feb. 11, 2021, the the Military Health System (MHS) announced partcipation in the AstraZeneca phase III clinical…
-
Clinical trial in hospitalized COVID-19 patients evaluate long-acting antibody therapy
On Feb. 8, 2021, the NIH announced that an international randomized, controlled Phase 3 clinical trial had begun…
-
NanoViricides’s antiviral drug candidate for treatment of COVID-19 infections well tolerated in animal safety studies
On Feb. 8, 2021, NanoViricides announced that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections…
-
Corvus Pharmaceuticals initiated phase 3 clinical trial of CPI-006 for patients with COVID-19
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
-
Johnson & Johnson announced submission of application to FDA for EUA of its single-shot COVID-19 vaccine candidate
On Feb. 4, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, had submitted an application to the…
-
Dynavax and Serum Institute announced first participant dosed in trial evaluating Tdap vaccine adjuvanted with CpG 1018
On Feb. 3, 2021, Dynavax Technologies and Serum Institute of India announced that the first participant has been…
-
First-in-human clinical trial confirmed novel HIV vaccine approach
On Feb. 3, 2021, IAVI and Scripps Research announced a phase 1 clinical trial testing a novel vaccine…
-
NeuroRx initiated phase 2/3 study of inhaled ZYESAMI for severe COVID-19 with UCI Health
On Feb. 3, 2021, RELIEF THERAPEUTICS affirmed that its collaboration partner NeuroRx had initiated a phase 2/3 clinical…
-
AXIM Biotechnologies began clinical trials of ImmunoPass rapid diagnostic test with vaccine recipients
On Feb. 3, 2021, AXIM Biotechnologies announced initiation of clinical trials for ImmunoPass, the Companyﾒs rapid point-of-care test…
-
Rigel awarded $165 Million from US DOD for phase 3 clinical trial of Fostamatinib in COVID-19 patients
On Jan. 29, 2021, Rigel Pharma announced it has been awarded $16.5 million by the U.S. Department of…
-
Innovation Pharmaﾒs phase 2 clinical trial of Brilacidin for treating COVID-19 began
On Jan. 29, 2021, Innovation Pharmaceuticals announced that the companyﾒs Phase 2 clinical trial of Brilacidin for treating…
-
Single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of phase 3 ENSEMBLE trial
On Jan. 29, 2021, Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE…
-
Novavax COVID-19 vaccine demonstrated 89.3% efficacy in UK phase 3 trial
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
-
OncoSec announced first subjects dosed in phase 1 trial of CORVax12, COVID-19 vaccine candidate
On Jan. 27, 2021, OncoSec Medical announced that it had dosed several subjects in its Phase 1 clinical…
